Share this Article
Kong QX, Xia M, Liang RQ, Li L, Cu X, Sun ZX, Hu J
Correspondence: Dr Qingxia Kong, qingxiakong56@126.com
ABSTRACT
INTRODUCTION The present study aimed to investigate the possible associations between serum levels of visfatin, an adipokine, and atherosclerosis in patients with ischaemic cerebrovascular disease.
METHODS A total of 95 participants were recruited for this study. Group A comprised 35 individuals with no history of cerebrovascular disease (control group) and Group B comprised 60 patients with ischaemic cerebrovascular disease. Group B was further categorised into two subgroups based on the ultrasonographic findings of the common carotid artery intima-media thickness (CCA-IMT) – Group B1 consisted of 21 patients with no atherosclerosis (i.e. CCA-IMT ≤ 0.9 mm) and Group B2 consisted of 39 patients with atherosclerosis (i.e. CCA-IMT > 0.9 mm). The body mass index, fasting blood total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and glucose levels of each patient were measured. Serum visfatin levels were determined using enzyme-linked immunosorbent assays. Visfatin levels were compared between groups, and stepwise logistic regression analysis was used to identify risk factors for atherosclerosis, including visfatin levels.
RESULTS The mean serum visfatin level of the patients in Group B was higher than that in Group A (75.5 ± 77.80 ng/mL vs. 8.6 ± 4.69 ng/mL; p < 0.05) and the level was higher in patients from Group B2 than those from Group B1 (89.0 ± 80.68 ng/mL vs. 50.4 ± 72.44 ng/mL; p < 0.05). Multivariate regression analysis showed that CCA-IMT values were not significantly associated with visfatin levels. However, logistic regression analysis showed that serum visfatin was an independent risk factor for atherosclerosis (odds ratio 37.80; p = 0.004).
CONCLUSION Serum visfatin may be an independent risk factor for cerebral infarction, as high serum visfatin levels are positively associated with the underlying pathogenic mechanisms of ischaemic cerebrovascular disease.
Keywords: adipocytokine, atherosclerosis, cerebral infarction, ischaemic cerebrovascular disease, visfatin
Singapore Med J 2014; 55(7): 383-387; http://dx.doi.org/10.11622/smedj.2014091
REFERENCES
| 1. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell 2001; 104:503-16. http://dx.doi.org/10.1016/S0092-8674(01)00238-0 | ||||
| 2. Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci 2009; 54:1847-56. http://dx.doi.org/10.1007/s10620-008-0585-3 | ||||
| 3. Samal B, Sun Y, Stearns G, et al. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994; 14:1431-7. PMid:8289818 PMCid:PMC358498 | ||||
| 4. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307:426-30. http://dx.doi.org/10.1126/science.1097243 | ||||
| 5. Sommer G, Garten A, Petzold S, et al. Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine. Clin Sci (Lond) 2008; 115:13-23. http://dx.doi.org/10.1042/CS20070226 | ||||
| 6. Sonoli SS, Shivprasad S, Prasad CV, et al. Visfatin-a review. Eur Rev Med Pharmacol Sci 2011; 15:9-14. PMid:21381495 | ||||
| 7. Zhang LQ, Heruth DP, Ye SQ. Nicotinamide phosphoribosyltransferase in human diseases. J Bioanal Biomed 2011; 3:13-25. http://dx.doi.org/10.4172/1948-593X.1000038 | ||||
| 8. Luk T, Malam Z, Marshall JC. Pre-B-cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J Leukoc Biol 2008; 83:804-16. http://dx.doi.org/10.1189/jlb.0807581 | ||||
| 9. Dahl T, Yndestad A, Skjelland M, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis. Possible role in inflammation and plaque destabilization. Circulation 2007; 115:972-80. http://dx.doi.org/10.1161/CIRCULATIONAHA.106.665893 | ||||
| 10. Adya R, Tan BK, Chen J, Randeva HS. Pre-B colony enhancing factor (PBEF)/visfatin induces secretion of MCP-1 in human endothelial cells: role in visfatin-induced angiogenesis. Atherosclerosis 2009; 205:113-9. http://dx.doi.org/10.1016/j.atherosclerosis.2008.11.024 | ||||
| 11. Kato A, Odamaki M, Ishida J, Hishida A. Relationship between serum pre-B cell colony-enhancing factor/visfatin and atherosclerotic parameters in chronic hemodialysis patients. Am J Nephrol 2009; 29:31-5. http://dx.doi.org/10.1159/000148648 | ||||
| 12. Zhong M, Tan HW, Gong HP, et al. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf) 2008; 69:878-84. http://dx.doi.org/10.1111/j.1365-2265.2008.03248.x | ||||
| 13. Lu LF, Yang SS, Wang CP, et al. Elevated visfatin/pre-B-cell colony-stimulating factor plasma concentration in ischemic stroke. J Stroke Cerebrovasc Dis 2009; 18:354-9. http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2009.01.003 | ||||
| 14. Li W. The fourth cerebrovascular diseases academic meeting of the Chinese Medical Association: Diagnostic points of various cerebrovascular diseases. Chinese J Neurol 1996; 29:379-80. | ||||
| 15. Mancia G, DeBacker G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28:1462-536. PMid:17562668 | ||||
| 16. Chen MP, Chung FM, Chang DM, et al. Elevated plasma levels of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91:295-9. http://dx.doi.org/10.1210/jc.2005-1475 | ||||
| 17. Chien KL, Su TC, Jeng JS, et al. Carotid artery intima-media thickness, carotid plaque and coronary heart disease and stroke in Chinese. PLoS One 2008; 3:e3435. http://dx.doi.org/10.1371/journal.pone.0003435 | ||||
| 18. La Favor JD, Hollis BC, Mokshagundam SL, Olive JL. Serum hsCRP and visfatin are elevated and correlate to arterial stiffness in spinal cord-injured subjects. Spinal Cord 2011; 49:961-6. http://dx.doi.org/10.1038/sc.2011.56 | ||||
| 19. Sethi JK, Vidal-Puig A. Visfatin: the missing link between intra-abdominal obesity and diabetes- Trends Mol Med 2005; 11:344-7. http://dx.doi.org/10.1016/j.molmed.2005.06.010 | ||||
| 20. Spiroglou SG, Kostopoulos CG, Varakis JN, Papadaki HH. Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis. J Atheroscler Thromb 2010; 17:115-30. http://dx.doi.org/10.5551/jat.1735 | ||||
| 21. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 2007; 56:451-8. http://dx.doi.org/10.1016/j.metabol.2006.12.001 | ||||
| 22. Van derVeer E, Nong Z, O'NeilC, et al. Pre-B-cell colony-enhancing factor regulates NAD+ dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Circ Res 2005; 97:25-34. http://dx.doi.org/10.1161/01.RES.0000173298.38808.27 | ||||
| 23. Liu SW, Qiao SB, Yuan JS, Liu DQ. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf). 2009; 71:202-7. http://dx.doi.org/10.1111/j.1365-2265.2008.03453.x | ||||
| 24. Filippatos TD, Randeva HS, Derdemezis CS, Elisaf MS, Mikhailidis DP. Visfatin/PBEF and atherosclerosis-related diseases. Curr Vasc Pharmacol 2010; 8:12-28. http://dx.doi.org/10.2174/157016110790226679 | ||||